Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sgc8-ICG
- Development stage
- Preclinical
- Lead developer
- Renji Hospital
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravesical
01
Overview
Sgc8-ICG is a novel fluorescent molecular probe developed for fluorescence cystoscopy to improve the detection and diagnosis of bladder cancer (urothelial carcinoma). It consists of the DNA aptamer Sgc8, which specifically targets protein tyrosine kinase 7 (PTK7)—a cell-membrane protein highly expressed in various cancers—covalently conjugated to the near-infrared fluorescent dye indocyanine green (ICG). By binding specifically to PTK7 on bladder cancer cells, Sgc8-ICG enables targeted fluorescence imaging of tumor tissues during cystoscopy, offering potentially higher sensitivity and specificity compared to conventional non-targeted photosensitizers like 5-ALA or hexaminolevulinate (HAL). Preclinical studies in orthotopic bladder cancer models and fresh human tissues have demonstrated its safety, rapid clearance, and effective tumor-targeting capabilities.
- Other names
- Sgc8-ICG fluorescent molecular probeSgc-8-ICG fluorescent molecular probeSgc 8-ICG fluorescent molecular probeSgc8-indocyanine greenSgc-8-indocyanine greenSgc 8-indocyanine greenSgc8-indocyanine green conjugateSgc-8-indocyanine green conjugateSgc 8-indocyanine green conjugate
02
Targets
PTK7 (Protein tyrosine kinase 7)
Beyond the preview
Go deeper on Sgc8-ICG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sgc8-ICG.